<?xml version="1.0" encoding="UTF-8"?>
<p>In cardiovascular complication, diuretic agents as loop diuretics, thiazide, and potassium-sparing diuretics are commonly considered to mitigate the exacerbation related to congestion and edema. Diuretics today are a well-reputed medication for the reduction of blood volume and venous pressure to treat essential hypertension and heart failure. In addition to their beneficial role in hypertension, diuretics also improve mortality associated with chronic kidney disease, pulmonary edema, stroke, and congestive heart failure [
 <xref rid="B5" ref-type="bibr">5</xref>]. Meanwhile, pharmacovigilance clinical data also assure that diuretics are commonly related to a variety of adverse effects, such as alteration in systemic electrolyte balance, hypovolemia, metabolic alkalosis or acidosis, and hyperuricemia [
 <xref rid="B6" ref-type="bibr">6</xref>]. So, in the era of modern medicine, it is necessary to design and develop new diuretic agents that not only improve the therapeutic outcome in cardiovascular morbidities but may also overcome the undesired effects and events.
</p>
